ArticleBMJ open2025

Low-dose radiation and stereotactic body radiotherapy with PD-1 inhibitor sintilimab and chemotherapy for first-line treatment of locally advanced or metastatic squamous lung cancer: protocol for a randomised phase II trial (IHC002 study).

Ruoxi Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.